Trembath R C, Thomson J R, Machado R D, Morgan N V, Atkinson C, Winship I, Simonneau G, Galie N, Loyd J E, Humbert M, Nichols W C, Morrell N W, Berg J, Manes A, McGaughran J, Pauciulo M, Wheeler L
Department of Medicine, University of Leicester, United Kingdom.
N Engl J Med. 2001 Aug 2;345(5):325-34. doi: 10.1056/NEJM200108023450503.
Most patients with familial primary pulmonary hypertension have defects in the gene for bone morphogenetic protein receptor II (BMPR2), a member of the transforming growth factor beta (TGF-beta) superfamily of receptors. Because patients with hereditary hemorrhagic telangiectasia may have lung disease that is indistinguishable from primary pulmonary hypertension, we investigated the genetic basis of lung disease in these patients.
We evaluated members of five kindreds plus one individual patient with hereditary hemorrhagic telangiectasia and identified 10 cases of pulmonary hypertension. In the two largest families, we used microsatellite markers to test for linkage to genes encoding TGF-beta-receptor proteins, including endoglin and activin-receptor-like kinase 1 (ALK1), and BMPR2. In subjects with hereditary hemorrhagic telangiectasia and pulmonary hypertension, we also scanned ALK1 and BMPR2 for mutations.
We identified suggestive linkage of pulmonary hypertension with hereditary hemorrhagic telangiectasia on chromosome 12q13, a region that includes ALK1. We identified amino acid changes in activin-receptor-like kinase 1 that were inherited in subjects who had a disorder with clinical and histologic features indistinguishable from those of primary pulmonary hypertension. Immunohistochemical analysis in four subjects and one control showed pulmonary vascular endothelial expression of activin-receptor-like kinase 1 in normal and diseased pulmonary arteries.
Pulmonary hypertension in association with hereditary hemorrhagic telangiectasia can involve mutations in ALK1. These mutations are associated with diverse effects, including the vascular dilatation characteristic of hereditary hemorrhagic telangiectasia and the occlusion of small pulmonary arteries that is typical of primary pulmonary hypertension.
大多数家族性原发性肺动脉高压患者的骨形态发生蛋白受体II(BMPR2)基因存在缺陷,BMPR2是转化生长因子β(TGF-β)超家族受体的成员。由于遗传性出血性毛细血管扩张症患者可能患有与原发性肺动脉高压难以区分的肺部疾病,我们对这些患者肺部疾病的遗传基础进行了研究。
我们评估了五个家系的成员以及一名患有遗传性出血性毛细血管扩张症的个体患者,共确定了10例肺动脉高压病例。在两个最大的家族中,我们使用微卫星标记来检测与编码TGF-β受体蛋白的基因(包括内皮糖蛋白和激活素受体样激酶1(ALK1))以及BMPR2的连锁关系。在患有遗传性出血性毛细血管扩张症和肺动脉高压的受试者中,我们还对ALK1和BMPR2进行了突变扫描。
我们发现肺动脉高压与12q13染色体上的遗传性出血性毛细血管扩张症存在提示性连锁关系,该区域包括ALK1。我们在激活素受体样激酶1中发现了氨基酸变化,这些变化在患有与原发性肺动脉高压临床和组织学特征难以区分的疾病的受试者中呈遗传状态。对四名受试者和一名对照进行的免疫组织化学分析显示,在正常和患病的肺动脉中,激活素受体样激酶1在肺血管内皮中表达。
与遗传性出血性毛细血管扩张症相关的肺动脉高压可能涉及ALK1突变。这些突变具有多种影响,包括遗传性出血性毛细血管扩张症特有的血管扩张以及原发性肺动脉高压典型的小肺动脉闭塞。